Overview
Modeling Center of Excellence Practices to Improve the Care of Patients With Biomarker-Driven Thyroid Cancer or Non-Small-Cell Lung Cancer
Registration is closed for this activity.
team practicing in academic and community settings who treat patients with NSCLC or thyroid cancer.
- Develop improved models for early and effective biomarker testing
- Identify appropriate patients and optimize treatment for RET-targeted therapy
- Develop strategies to mitigate challenges and barriers to optimizing RET testing for patients with NSCLC and thyroid cancer
Attending Pathologist and Laboratory Director, Diagnostic Molecular Pathology
Medical Director, Molecular Hematopathology
Memorial Sloan Kettering Cancer Center
New York, NY
Consultant: AstraZeneca, Bristol Myers Squibb, CVS, Daiichi Sankyo, EMD Sereono, Gilead, Mirati, Novocure, Regeneron, Sanofi, Takeda, Tempus
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Pralsetinib is not approved for the treatment of advanced/metastatic dedullary thryroid cancer
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. The University of Chicago and ACHL require the speaker to disclose that a product is not labeled for the use under discussion.
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.